Wogonin mitigates nonalcoholic fatty liver disease via enhancing PPARα/AdipoR2, in vivo and in vitro.

  • Jing Chen, Jie Liu, +5 authors Yancheng Xu
  • Published 2017 in
    Biomedicine & pharmacotherapy = Biomedecine…

Abstract

Wogonin has been reported to attenuate hyperglycemia in diabetic mice via anti-adipogenic effect on adipocytes. The potential therapeutic role of wogonin in nonalcoholic fatty liver disease (NAFLD) remains obscure. The aim of the present study was to explore the protective effect of wogonin on NAFLD mice and cultured NCTC 1469 cells exposed to palmitate… (More)
DOI: 10.1016/j.biopha.2017.04.125

Cite this paper

@article{Chen2017WogoninMN, title={Wogonin mitigates nonalcoholic fatty liver disease via enhancing PPARα/AdipoR2, in vivo and in vitro.}, author={Jing Chen and Jie Liu and Ye Wang and Xuemei Hu and Feng Zhou and Yimeng Hu and Yin Yuan and Yancheng Xu}, journal={Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie}, year={2017}, volume={91}, pages={621-631} }